EP0182024A2 — Purine derivatives and their pharmaceutical use
Assigned to Novartis International Pharmaceutical Ltd · Expires 1986-05-28 · 40y expired
What this patent protects
1. A compound of formula (I) or a salt thereof, wherein R, and R 2 are each independently hydrogen, acyl or phosphate, provided that when one of R, or R, is phosphate, the other is hydrogen; or R, and R 2 are joined together to form a cyclic acetal group, a cyclic carbonat…
USPTO Abstract
1. A compound of formula (I) or a salt thereof, wherein R, and R 2 are each independently hydrogen, acyl or phosphate, provided that when one of R, or R, is phosphate, the other is hydrogen; or R, and R 2 are joined together to form a cyclic acetal group, a cyclic carbonate group or a cyclic phosphate group. Processes for preparing these compounds and their use in therapy is also described.
Drugs covered by this patent
- Sustiva (EFAVIRENZ) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.